Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention
2017; Lippincott Williams & Wilkins; Volume: 137; Issue: 3 Linguagem: Inglês
10.1161/circulationaha.117.031678
ISSN1524-4539
AutoresJohn W. McEvoy, Ibrahim Khalil, Thomas S. Kickler, William Clarke, Rani K. Hasan, Matthew J. Czarny, Ali R. Keramati, Rakesh R. Goli, Travis P. Gratton, Jeffrey Brinker, Matthews Chacko, Chao‐Wei Hwang, Peter V. Johnston, Julie M. Miller, Jeffrey C. Trost, William R. Herzog, Roger S. Blumenthal, David R. Thiemann, Jon R. Resar, Steven P. Schulman,
Tópico(s)Coronary Interventions and Diagnostics
ResumoHomeCirculationVol. 137, No. 3Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBEffect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary InterventionThe PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl) John W. McEvoy, MBBCh, MEHP, MHS, Khalil Ibrahim, MD, Thomas S. Kickler, MD, William A. Clarke, PhD, Rani K. Hasan, MD, MHS, Matthew J. Czarny, MD, Ali R. Keramati, MD, Rakesh R. Goli, BA, Travis P. Gratton, MD, Jeffrey A. Brinker, MD, Matthews Chacko, MD, Chao-Wei Hwang, MD, PhD, Peter V. Johnston, MD, Julie M. Miller, MD, Jeffrey C. Trost, MD, William R. Herzog, MD, Roger S. Blumenthal, MD, David R. Thiemann, MD, Jon R. Resar, MD and Steven P. Schulman, MD John W. McEvoyJohn W. McEvoy Ciccarone Center for the Prevention of Heart Disease (J.W.M., R.S.B.) Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) Johns Hopkins University School of Medicine, Baltimore, MD. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (J.W.M.). , Khalil IbrahimKhalil Ibrahim Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Thomas S. KicklerThomas S. Kickler Department of Pathology (T.S.K., W.A.C.) , William A. ClarkeWilliam A. Clarke Department of Pathology (T.S.K., W.A.C.) , Rani K. HasanRani K. Hasan Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Matthew J. CzarnyMatthew J. Czarny Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Ali R. KeramatiAli R. Keramati Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Rakesh R. GoliRakesh R. Goli Department of Medicine (R.R.G., T.P.G.) , Travis P. GrattonTravis P. Gratton Department of Medicine (R.R.G., T.P.G.) , Jeffrey A. BrinkerJeffrey A. Brinker Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Matthews ChackoMatthews Chacko Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Chao-Wei HwangChao-Wei Hwang Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Peter V. JohnstonPeter V. Johnston Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Julie M. MillerJulie M. Miller Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Jeffrey C. TrostJeffrey C. Trost Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , William R. HerzogWilliam R. Herzog Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Roger S. BlumenthalRoger S. Blumenthal Ciccarone Center for the Prevention of Heart Disease (J.W.M., R.S.B.) Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , David R. ThiemannDavid R. Thiemann Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) , Jon R. ResarJon R. Resar Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) and Steven P. SchulmanSteven P. Schulman Division of Cardiology, Department of Medicine (J.W.M., K.I., R.K.H., M.J.C., A.R.K., J.A.B., M.C., C.-W.H., P.V.J., J.M.M., J.C.T., W.R.H., R.S.B., D.R.T., J.R.R., S.P.S.) Originally published18 Oct 2017https://doi.org/10.1161/CIRCULATIONAHA.117.031678Circulation. 2018;137:307–309Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2017: Previous Version 1 Fentanyl is a potent opiate commonly administered during cardiac catheterization procedures in North America.1 The question of whether fentanyl could have adverse consequences in patients undergoing percutaneous coronary intervention (PCI) is raised by recent research demonstrating that intravenous morphine significantly delays the absorption of oral P2Y12 platelet inhibitors.2 The presumed mechanism is slowed gastric emptying.The single-center PACIFY trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl; ClinicalTrials.gov. Unique identifier: NCT02683707) randomized adults undergoing clinically indicated elective coronary angiography to receive the procedure with or without intravenous fentanyl.3 The study was approved by the Johns Hopkins Medicine Institutional Review Board, and all participants provided written informed consent. Eligible adults had not received P2Y12 inhibitors for 14 days before enrollment. Other exclusion criteria included preprocedural treatment with oral anticoagulants or opiates, platelet count <100 000/mm3, and impaired renal or hepatic function. All participants received subcutaneous lidocaine and intravenous midazolam at the start of the catheterization procedure and as needed thereafter. Doses of all drugs were at the discretion of treating providers. Patients and outcomes assessors were blinded; treating providers were not. Participants who required PCI received an oral dose of 180 mg ticagrelor at the conclusion of diagnostic angiography.Blood samples were collected at baseline and 0.5, 1, 2, 4, and 24 hours after the ticagrelor load. Ticagrelor plasma concentrations were measured by liquid chromatography–tandem mass spectrometry, and platelet function was assessed with the VerifyNow system at each time point. Platelet function was also assessed at the 2-hour time point with light transmission aggregometry. The prespecified primary outcome was ticagrelor concentration during the 24 hours after loading, as assessed by the area under the concentration-time curve. Prespecified secondary end points included platelet inhibition assessed by VerifyNow P2Y12 reaction units at 2 hours, platelet inhibition assessed by aggregometry (percent change from baseline aggregation with ADP) at 2 hours, and self-reported maximum pain experienced during the procedure on a numeric scale of 0 to 10. Between-group comparisons were made with the Fisher exact test for categorical variables and t test or Wilcoxon rank-sum test for continuous variables. The level of significance was P<0.05 (2 sided).Of the 212 participants randomized, 70 required PCI and were loaded with ticagrelor; these 70 subjects represent the modified intention-to-treat study population. Mean age was 63 years; 27% were female; and most were white. No differences in demographics were seen between the fentanyl and no fentanyl arms (data not shown). The fentanyl arm had a lower ticagrelor 24-hour area under the concentration-time curve than the no fentanyl arm (2107 versus 3301 ng·h−1 mL; P=0.05; Figure). The 2-hour mean±SD P2Y12 reaction unit value was 112±95 in the fentanyl arm compared with 78±72 in the no fentanyl arm (P=0.09). ADP response by aggregometry was greater with fentanyl versus no fentanyl (39.3±8.7% versus 27.5±14.4%; P=0.04). These differences yielded higher rates of 2-hour high platelet reactivity in the fentanyl arm (20% versus 6% by PRU [P=0.07] and 33% versus 5% by aggregometry [P=0.03]; Figure). By 4 hours, P2Y12 reaction unit values were similar in both arms (55 for fentanyl versus 50 for no fentanyl; P=0.73).Download figureDownload PowerPointFigure. Primary and secondary end points.A, Plasma concentrations of ticagrelor (means and SEs) after a 180-mg oral load according to fentanyl randomization. The area under the concentration-time curve (AUC) P value is for the difference in AUC[0–24] between the study arms. The P values above each SE bar are for differences in mean ticagrelor concentration at each time point. B, High platelet reactivity 2 hours after 180-mg ticagrelor loading according to fentanyl randomization, assessed by both VerifyNow (P2Y12 reaction units [PRU] ≥235) and light-transmission aggregometry (≥46% change from baseline aggregation in response to ADP).Mean self-reported maximal intraprocedural pain was 1.5 (on a 10-point numeric scale) with fentanyl versus 2.3 without fentanyl (P=0.14). Mean±SD high-sensitivity troponin-I levels at 2 hours were 12.1±9.5 ng/L with fentanyl versus 6.7±4.2 ng/L without fentanyl (P=0.02). One patient in the fentanyl arm had acute stent thrombosis, and another had a catheter thrombosis. There were no thrombotic events in the no fentanyl arm.This trial demonstrates that fentanyl administration lowers plasma concentrations of ticagrelor and delays its antiplatelet effects. Our results extend previous studies reporting that morphine delays the absorption of clopidogrel, ticagrelor, and prasugrel and impairs P2Y12 inhibition.2,4,5 These findings for fentanyl, a faster-acting medication that is routinely used in US catheterization laboratories,1 have potential clinical implications. The PACIFY trial describes an important new drug-drug interaction to be considered in the catheterization laboratory. The higher postprocedural high-sensitivity troponin-I levels highlight the potential clinical relevance of this interaction. The PACIFY trial results suggest that routine use of fentanyl should be discouraged during PCI in the absence of pain, particularly when P2Y12 agents are loaded near the time of administration of opiates. The practice of prophylactic fentanyl at the start of catheterization and PCI procedures may require reconsideration, although we cannot advocate withholding this opiate when necessary for the treatment of pain.Larger studies are now needed to evaluate the effect of the coadministration of fentanyl and ticagrelor on clinical end points, including stent thrombosis. We did not power this study for pain outcomes, although the numeric differences were small. In conclusion, routine use of fentanyl for PCI sedation reduces ticagrelor absorption and delays platelet inhibition in patients undergoing PCI without significant evidence of improvement in subjective comfort.John W. McEvoy, MBBCh, MEHP, MHSKhalil Ibrahim, MDThomas S. Kickler, MDWilliam A. Clarke, PhDRani K. Hasan, MD, MHSMatthew J. Czarny, MDAli R. Keramati, MDRakesh R. Goli, BATravis P. Gratton, MDJeffrey A. Brinker, MDMatthews Chacko, MDChao-Wei Hwang, MD, PhDPeter V. Johnston, MDJulie M. Miller, MDJeffrey C. Trost, MDWilliam R. Herzog, MDRoger S. Blumenthal, MDDavid R. Thiemann, MDJon R. Resar, MDSteven P. Schulman, MDAcknowledgmentsThe investigators thank the patients who participated in this study for their critical contribution. Drs McEvoy and Schulman thank their research coordinator, Frances A. Kirkland, without whom this study would not have been possible. Dr McEvoy also acknowledges Dr Cian P. McCarthy, who stimulated his interest in the interaction between opiates and oral P2Y12 inhibitors.Sources of FundingPACIFY was fully funded by an institutional grant awarded to Dr McEvoy from the Johns Hopkins Magic That Matters Research Fund.DisclosuresNone.FootnotesThe data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results.Circulation is available at http://circ.ahajournals.org.Correspondence to: John W. McEvoy, MBBCh, MEHP, MHS, Assistant Professor of Medicine, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Blalock 524C, Baltimore, MD 21287. E-mail [email protected]References1. Lavi S, Jolly SS, Bainbridge D, Manji F, Randhawa V, Lavi R. Sedation, analgesia, and anaesthesia variability in laboratory-based cardiac procedures: an international survey.Can J Cardiol. 2014; 30:627–633. doi: 10.1016/j.cjca.2014.03.034.CrossrefMedlineGoogle Scholar2. McCarthy CP, Mullins KV, Sidhu SS, Schulman SP, McEvoy JW. The on- and off-target effects of morphine in acute coronary syndrome: a narrative review.Am Heart J. 2016; 176:114–121. doi: 10.1016/j.ahj.2016.04.004.CrossrefMedlineGoogle Scholar3. Ibrahim K, Goli RR, Shah R, Resar JR, Schulman SP, McEvoy JW. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: design, rationale, and sample characteristics of the PACIFY randomized trial.Contemp Clin Trials. 2018; 64:8–12. doi: 10.1016/j.cct.2017.11.011.CrossrefMedlineGoogle Scholar4. Hobl EL, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, Sunder-Plassmann R, Jilma-Stohlawetz P, Mannhalter C, Posch M, Jilma B. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial.J Am Coll Cardiol. 2014; 63:630–635. doi: 10.1016/j.jacc.2013.10.068.CrossrefMedlineGoogle Scholar5. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszałł MP, Rość D, Koziński M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.Eur Heart J. 2016; 37:245–252. doi: 10.1093/eurheartj/ehv547.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Cantor W, Tan M, Berwanger O, Lavi S, White H, Nicolau J, Dehghani P, Tajer C, Lopes R, Moia D, Nicholls S, Parkhomenko A, Averkov O, Brass N, Lutchmedial S, Malaga G, Damiani L, Piegas L, Granger C and Goodman S (2022) Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial, American Heart Journal, 10.1016/j.ahj.2022.05.005, 251, (1-12), Online publication date: 1-Sep-2022. Claessen B, Beerkens F and Henriques J (2022) Vasoactive and Antiarrhythmic Drugs During PCI Interventional Cardiology, 10.1002/9781119697367.ch41, (446-452), Online publication date: 3-Jun-2022. Fabris E, Selvarajah A, Tavenier A, Hermanides R, Kedhi E, Sinagra G and van't Hof A (2022) Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach, American Journal of Cardiovascular Drugs, 10.1007/s40256-022-00531-y Laurent D, Dodd W, Small C, Gooch M, Ghosh R, Goutnik M, Blatt T, Porche K, Geh N, Adamczak S, Polifka A, Brzezicki G, Hoh B and Chalouhi N (2021) Ticagrelor resistance: a case series and algorithm for management of non-responders, Journal of NeuroInterventional Surgery, 10.1136/neurintsurg-2021-017638, 14:2, (179-183), Online publication date: 1-Feb-2022. Tavenier A, Hermanides R, Ottervanger J, Tolsma R, van Beurden A, Slingerland R, ter Horst P, Gosselink A, Dambrink J, van Leeuwen M, Roolvink V, Kedhi E, Klungel O, Belitser S, Angiolillo D, Pustjens T, Rasoul S, Gho B, Stein M, Ruiters L and van 't Hof A (2020) Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial, European Heart Journal - Cardiovascular Pharmacotherapy, 10.1093/ehjcvp/pvaa095, 8:1, (4-12), Online publication date: 5-Jan-2022. Jensen I, Wu E, Cyr P, Claussen M, Winkler T, Salahuddin K, Prats J, Mahaffey K, Gibson C, Steg P, Stone G and Bhatt D (2021) Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective, American Journal of Cardiovascular Drugs, 10.1007/s40256-021-00491-9, 22:1, (93-104), Online publication date: 1-Jan-2022. Selvarajah A, Tavenier A, Bor W, Houben V, Rasoul S, Kaplan E, Teeuwen K, Hofma S, Lipsic E, Amoroso G, van Leeuwen M, Berg J, van 't Hof A and Hermanides R (2021) Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry, BMC Cardiovascular Disorders, 10.1186/s12872-021-02093-4, 21:1, Online publication date: 1-Dec-2021. Barbarash O, Komarov A, Panchenko E, Staroverov I, Shahnovich R and Yavelov I (2021) Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS), Eurasian heart journal, 10.38109/2225-1685-2021-4-6-59:4, (6-59) Galli M and Angiolillo D (2021) Non-opioid analgesics in patients undergoing percutaneous coronary intervention: hype or hope?, European Heart Journal, 10.1093/eurheartj/ehab595, 42:39, (4037-4039), Online publication date: 14-Oct-2021. Bangalore S, Barsness G, Dangas G, Kern M, Rao S, Shore-Lesserson L and Tamis-Holland J (2021) Evidence-Based Practices in the Cardiac Catheterization Laboratory: A Scientific Statement From the American Heart Association, Circulation, 144:5, (e107-e119), Online publication date: 3-Aug-2021. Black W, Baljepally R, Shali L, Alsharif O, Warden S, Heidel E, Zhao X and Zhou S (2021) Old Is (Not) Gold: Midazolam Monotherapy versus Midazolam Plus Fentanyl for Sedation during Cardiac Catheterization, Journal of Interventional Cardiology, 10.1155/2021/9932171, 2021, (1-6), Online publication date: 2-Aug-2021. Capranzano P and Angiolillo D (2021) Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2021.1920925, 19:6, (519-535), Online publication date: 3-Jun-2021. Hollier R, Sealy M, Ross N and Ebbs P (2021) Prehospital clopidogrel use and STEMI management: a review, Journal of Paramedic Practice, 10.12968/jpar.2021.13.6.CPD1, 13:6, (1-10), Online publication date: 2-Jun-2021. Buckley J, Mylotte D and McEvoy J (2021) Platelets and poppies: Do morphine and fentanyl differ?, International Journal of Cardiology, 10.1016/j.ijcard.2021.03.037, 333, (43-44), Online publication date: 1-Jun-2021. Sauer F, Jesel L, Marchandot B, Derimay F, Bochaton T, Amaz C, Roubille F, Cayla G, Rioufol G, Garcia-Dorado D, Claeys M, Angoulvant D, Bonnefoy-Cudraz E, Guérin P, Trinh A, Matsushita K, Ohlmann P, Jossan C, Mewton N, Ovize M and Morel O (2020) Life-threatening arrhythmias in anterior ST-segment elevation myocardial infarction patients treated by percutaneous coronary intervention: adverse impact of morphine, European Heart Journal. Acute Cardiovascular Care, 10.1093/ehjacc/zuaa005, 10:4, (427-436), Online publication date: 25-May-2021. Huang B, Qian Y, Xie S, Ye X, Chen H, Chen Z, Zhang L, Xu J, Hu H, Ma S, Héroux P, Wang D, Shen H, Wu Y and Xia D (2020) Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathway, Cellular & Molecular Immunology, 10.1038/s41423-020-0444-5, 18:5, (1278-1289), Online publication date: 1-May-2021. Senguttuvan N, Suman F, Paneerselvam T, Malepati B, Ramesh S, Vallivedu M, Badimela P, Ramadoss M, Iyer M, Krishnamurthy P, Vinod Kumar B, Balasubramaniyan J, Sadhanandham S, Jebaraj R, Manokar P, Muralidharan T, Murthy J, Thanikachalam S, Krishnamoorthy P, Baber U and Karthikeyan G (2021) Comparison of the effect of Morphine and Fentanyl in patients with acute coronary syndrome receiving Ticagrelor - The COMET (Comparison Morphine, Fentanyl and Ticagrelor) randomized controlled trial, International Journal of Cardiology, 10.1016/j.ijcard.2021.02.037, 330, (1-6), Online publication date: 1-May-2021. Tavenier A, Hermanides R, Fabris E, Angiolillo D and van 't Hof A (2021) Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI, International Journal of Cardiology, 10.1016/j.ijcard.2020.11.042, 328, (40-45), Online publication date: 1-Apr-2021. Ranka S, Dalia T, Acharya P, Taduru S, Pothuru S, Mahmood U, Stack B, Shah Z and Gupta K (2021) Comparison of Hospitalization Trends and Outcomes in Acute Myocardial Infarction Patients With Versus Without Opioid Use Disorder, The American Journal of Cardiology, 10.1016/j.amjcard.2020.12.077, 145, (18-24), Online publication date: 1-Apr-2021. Sealy M and Hollier R (2021) Appropriateness of oral clopidogrel for prehospital STEMI management, International Paramedic Practice, 10.12968/ippr.2021.11.1.4, 11:1, (4-14), Online publication date: 2-Mar-2021. Soo Kim B, Auerbach D, Sadhra H, Godwin M, Bhandari R, Ling F, Mohan A, Yule D, Wagner L, Rich D, Ture S, Morrell C, Timpanaro-Perrotta L, Younis A, Goldenberg I and Cameron S (2020) Sex-Specific Platelet Activation Through Protease-Activated Receptors Reverses in Myocardial Infarction, Arteriosclerosis, Thrombosis, and Vascular Biology, 41:1, (390-400), Online publication date: 1-Jan-2021. Voetsch A, Pregartner G, Berghold A, Seitelberger R, Schoerghuber M, Toller W and Mahla E (2021) How Do Type of Preoperative P2Y12 Receptor Inhibitor and Withdrawal Time Affect Bleeding?, The Annals of Thoracic Surgery, 10.1016/j.athoracsur.2020.04.126, 111:1, (77-84), Online publication date: 1-Jan-2021. Iglesias J, Valgimigli M, Carbone F, Lauriers N, Giorgio Masci P and Degrauwe S (2020) Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction, Circulation, 142:25, (2479-2481), Online publication date: 22-Dec-2020. Yan W, Yang S, Chen L and Yang J (2020) Analgesia in acute ischemic chest pain, Coronary Artery Disease, 10.1097/MCA.0000000000000887, 31:6, (556-564), Online publication date: 1-Sep-2020. Furtado R, Nicolau J, Guo J, Im K, White J, Sabatine M, Newby L and Giugliano R (2020) Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography, Journal of the American College of Cardiology, 10.1016/j.jacc.2019.11.035, 75:3, (289-300), Online publication date: 1-Jan-2020. Marian M, Abu Daya H, Chatterjee A, Al Solaiman F, Sasse M, Fonbah W, Workman R, Johnson B, Carlson S, Brott B, Prabhu S and Leesar M (2019) Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial, Journal of the American Heart Association, 8:23, Online publication date: 3-Dec-2019. Brener M, Tung J, Stant J, Sayan O, Suh E, Minutello R, Sharma R, Brener S, Melniker L, Moustakakis E, Neuberg G, Breen L, Nutovits R, Kats Y, Amaranto A, Pucillo A, Kirtane A and Rabbani L (2019) An Updated Healthcare System-Wide Clinical Pathway for Managing Patients With Chest Pain and Acute Coronary Syndromes, Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 10.1097/HPC.0000000000000189, 18:4, (167-175), Online publication date: 1-Dec-2019. Adamski P, Buszko K, Sikora J, Niezgoda P, Fabiszak T, Ostrowska M, Barańska M, Karczmarska-Wódzka A, Navarese E and Kubica J (2019) Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor, Scientific Reports, 10.1038/s41598-019-40628-0, 9:1, Online publication date: 1-Dec-2019. Han Y, Yan W, Zheng Y, Khan M, Yuan K and Lu L (2019) The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies, Translational Psychiatry, 10.1038/s41398-019-0625-0, 9:1, Online publication date: 1-Dec-2019. Franchi F, Rollini F, Park Y, Hu J, Kureti M, Rivas Rios J, Faz G, Yaranov D, Been L, Pineda A, Suryadevara S, Soffer D, Zenni M, Bass T and Angiolillo D (2019) Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine, JACC: Cardiovascular Interventions, 10.1016/j.jcin.2019.05.028, 12:16, (1538-1549), Online publication date: 1-Aug-2019. Hu T, Peeters S, Nagasawa D, Kamdar N, Brook R, Sun J, Park S, Moreland N, Cruz D, Macyszyn L and Press M (2019)(2019) Cangrelor Bridging Within 6 Months of a Drug-Eluting Stent in a Patient for Emergency Cervical Spine Surgery: A Case Report, A&A Practice, 10.1213/XAA.0000000000000994, 13:2, (69-73), Online publication date: 15-Jul-2019. Degrauwe S, Roffi M, Lauriers N, Muller O, Masci P, Valgimigli M and Iglesias J (2018) Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial, European Heart Journal - Cardiovascular Pharmacotherapy, 10.1093/ehjcvp/pvy031, 5:3, (158-163), Online publication date: 1-Jul-2019. Koh J, Fernando H, Peter K and Stub D (2019) Opioids and ST Elevation Myocardial Infarction: A Systematic Review, Heart, Lung and Circulation, 10.1016/j.hlc.2018.12.015, 28:5, (697-706), Online publication date: 1-May-2019. Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M, Shaikh Z, Nawaz A, Silva G, Been L, Smairat R, Kaufman M, Pineda A, Suryadevara S, Soffer D, Zenni M, Bass T and Angiolillo D (2019) Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention, Circulation, 139:14, (1661-1670), Online publication date: 2-Apr-2019. Tavenier A, Hermanides R, Ottervanger J, Rasoul S, Slingerland R, Tolsma R, van Workum S, Kedhi E and van 't Hof A (2019) A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial, Netherlands Heart Journal, 10.1007/s12471-019-1241-6, 27:4, (185-190), Online publication date: 1-Apr-2019. Smith T, Johnson J, Habtewold A and Burmeister M (2019) Cardiovascular Risk Reduction, Critical Care Nursing Clinics of North America, 10.1016/j.cnc.2018.11.001, 31:1, (15-30), Online publication date: 1-Mar-2019. Wong G, Welsford M, Ainsworth C, Abuzeid W, Fordyce C, Greene J, Huynh T, Lambert L, Le May M, Lutchmedial S, Mehta S, Natarajan M, Norris C, Overgaard C, Perry Arnesen M, Quraishi A, Tanguay J, Traboulsi M, van Diepen S, Welsh R, Wood D, Cantor W, Armstrong P, Bagai A, Bainey K, Cairns J, Cheskes S, Ducas J, Dzavik V, Jolly S, McVey J, Schampaert E, Schnell G and So D (2019) 2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion, Canadian Journal of Cardiology, 10.1016/j.cjca.2018.11.031, 35:2, (107-132), Online publication date: 1-Feb-2019. Holm M, Tornvall P, Henareh L, Jensen U, Golster N, Alström P, Santos‐Pardo I, Witt N, Fedchenko N, Venetsanos D, Beck O and van der Linden J (2019) The MOVEMENT Trial, Journal of the American Heart Association, 8:2, Online publication date: 22-Jan-2019. Gremmel T, Bhatt D and Michelson A (2019) Laboratory Monitoring of Antiplatelet Therapy Platelets, 10.1016/B978-0-12-813456-6.00036-9, (653-682), . Tavenier A, Hermanides R, Ottervanger J, Ter Horst P, Kedhi E and van 't Hof A (2018) Risks of Opioids in ST-Elevation Myocardial Infarction: A Review, Drug Safety, 10.1007/s40264-018-0710-y, 41:12, (1303-1308), Online publication date: 1-Dec-2018. Zuin M, Rigatelli G and Roncon L (2018) Use of Fentanyl During Percutaneous Coronary Interventions: Safety and Drawbacks, Cardiovascular Drugs and Therapy, 10.1007/s10557-018-6835-5, 32:6, (625-632), Online publication date: 1-Dec-2018. Ibrahim K, Shah R and McEvoy J (2018) Response by Ibrahim et al to Letter Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)", Circulation, 138:2, (216-217), Online publication date: 10-Jul-2018.Kikkert W, Delewi R and Claessen B (2018) Letter by Kikkert et al Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)", Circulation, 138:2, (214-215), Online publication date: 10-Jul-2018. Bartko J, Schoergenhofer C, Schwameis M, Wadowski P, Kubica J, Jilma B and Hobl E (2018) Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers, Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.117.247213, 365:2, (430-436), Online publication date: 1-May-2018. January 16, 2018Vol 137, Issue 3 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.117.031678PMID: 29046319 Originally publishedOctober 18, 2017 Keywordsticagrelorblood plateletsfentanylpercutaneous coronary interventionPDF download Advertisement SubjectsCatheter-Based Coronary and Valvular InterventionsPercutaneous Coronary InterventionPharmacology
Referência(s)